PapersFlow Research Brief
Pituitary Gland Disorders and Treatments
Research Guide
What is Pituitary Gland Disorders and Treatments?
Pituitary gland disorders and treatments encompass a range of conditions caused by dysfunction of the pituitary gland, including hormone overproduction or deficiency leading to syndromes such as Cushing's syndrome, acromegaly, hyperprolactinemia, hypopituitarism, and tumors like prolactinomas and adenomas, managed through diagnostic testing, medical therapies, surgery, and radiotherapy.
Pituitary gland disorders affect hormone secretion from the pituitary, resulting in conditions like acromegaly from excess growth hormone and Cushing's syndrome from excess cortisol. The field includes 98,895 published works addressing diagnosis and management of these disorders. Clinical practice guidelines provide standardized approaches for testing and treatment of specific disorders such as hyperprolactinemia and pheochromocytoma.
Research Sub-Topics
Cushing's Syndrome Diagnosis
This sub-topic covers biochemical testing, imaging modalities, and differential diagnosis strategies for identifying endogenous hypercortisolism. Researchers study validation of diagnostic algorithms, salivary cortisol measurements, and late-night cortisol testing protocols.
Acromegaly Treatment Guidelines
This sub-topic examines surgical, medical, and radiation therapies for growth hormone excess, including somatostatin analogs and GH receptor antagonists. Researchers investigate biochemical control rates, tumor shrinkage efficacy, and long-term comorbidity management.
Hyperprolactinemia Management
This sub-topic addresses dopamine agonist therapy, prolactinoma surgery, and cabergoline resistance mechanisms. Researchers explore neuroimaging protocols, fertility outcomes, and long-term tumor recurrence risks.
Multiple Endocrine Neoplasia Type 1
This sub-topic focuses on MEN1 gene mutations, parathyroid and pituitary tumor screening, and surveillance protocols. Researchers study genotype-phenotype correlations, pancreatic neuroendocrine tumor management, and prophylactic strategies.
Hypopituitarism Hormone Replacement
This sub-topic covers glucocorticoid, thyroid, gonadal, and growth hormone replacement regimens post-pituitary surgery or apoplexy. Researchers evaluate dosing optimization, cardiovascular risk modification, and quality-of-life outcomes.
Why It Matters
Pituitary gland disorders disrupt multiple endocrine axes, leading to symptoms like abnormal growth in acromegaly, weight gain and hypertension in Cushing's syndrome, and infertility in hyperprolactinemia, necessitating precise diagnosis and targeted therapies to prevent complications such as cardiovascular disease and vision loss. Katznelson et al. (2014) in "Acromegaly: An Endocrine Society Clinical Practice Guideline" outline biochemical assessments and therapeutic algorithms using somatostatin analogs or surgery for growth hormone excess caused by pituitary adenomas. The FDA approved paltusotine (Palsonify) in September 2025 as the first once-daily oral somatostatin receptor ligand for acromegaly, enabling primary medical therapy for patients with pituitary adenomas secreting excess growth hormone. Lenders et al. (2014) recommend plasma free metanephrines for diagnosing pheochromocytoma and paraganglioma, which can associate with pituitary disorders in syndromes like MEN1 identified by Chandrasekharappa et al. (1997). These guidelines and approvals improve patient outcomes by standardizing care and introducing convenient treatments.
Reading Guide
Where to Start
"Acromegaly: An Endocrine Society Clinical Practice Guideline" by Katznelson et al. (2014) provides a clear evidence-based overview of evaluation, biochemical testing, and management algorithms for a common pituitary disorder caused by growth hormone excess, making it accessible for initial understanding.
Key Papers Explained
Katznelson et al. (2014) "Acromegaly: An Endocrine Society Clinical Practice Guideline" builds on diagnostic foundations from Nieman et al. (2008) "The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline" by extending evidence-based algorithms to growth hormone disorders, while Melmed et al. (2011) "Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline" complements both with prolactin-specific protocols. Lenders et al. (2014) "Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline" connects via syndrome overlaps like MEN1 detailed in Chandrasekharappa et al. (1997) "Positional Cloning of the Gene for Multiple Endocrine Neoplasia-Type 1", which identifies genetic bases for multifocal pituitary involvement. Jonklaas et al. (2014) addresses hormone replacement for deficiencies arising from these tumors.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent FDA approvals of paltusotine as the first once-daily oral therapy for acromegaly in September 2025 target pituitary adenomas with excess growth hormone. Preprints highlight challenges like research silos impeding Cushing disease treatments and call for collaborative studies on pituitary neuroendocrine tumors. Advances include deep learning for pituitary tumor segmentation from MRI and classification into types like pituitary tumors using datasets of 7,023 images.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM | 1953 | The Journal of Clinica... | 3.8K | ✓ |
| 2 | Pheochromocytoma and Paraganglioma: An Endocrine Society Clini... | 2014 | The Journal of Clinica... | 2.7K | ✓ |
| 3 | The Diagnosis of Cushing's Syndrome: An Endocrine Society Clin... | 2008 | The Journal of Clinica... | 2.6K | ✓ |
| 4 | Positional Cloning of the Gene for Multiple Endocrine Neoplasi... | 1997 | Science | 2.1K | ✕ |
| 5 | Homocysteine and Atherothrombosis | 1998 | New England Journal of... | 2.0K | ✕ |
| 6 | Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Di... | 2000 | Archives of General Ps... | 2.0K | ✕ |
| 7 | Subclinical Thyroid Disease | 2004 | JAMA | 1.8K | ✕ |
| 8 | Guidelines for the Treatment of Hypothyroidism: Prepared by th... | 2014 | Thyroid | 1.8K | ✓ |
| 9 | Diagnosis and Treatment of Hyperprolactinemia: An Endocrine So... | 2011 | The Journal of Clinica... | 1.7K | ✓ |
| 10 | Acromegaly: An Endocrine Society Clinical Practice Guideline | 2014 | The Journal of Clinica... | 1.7K | ✓ |
In the News
FDA approves new treatment for acromegaly, a rare ...
Acromegaly is a rare endocrine disorder that causes some bones, organs, and other tissue to grow bigger. The pituitary gland in the brain causes these changes by making too much growth hormone (GH)...
FDA Approves Crinetics' Once-Daily Acromegaly Treatment
it.
FDA Approves Crinetics Acromegaly Drug
Acromegaly is typically caused by a pituitary adenoma, a benign tumor in the pituitary gland that secretes excessive growth hormone. This, in turn, triggers the overproduction of IGF-1 in the liver...
Palsonify (Paltusotine) Wins FDA Approval as an Oral ...
Acromegaly is a rare disease where a tumor in the pituitary gland makes too much growth hormone.
FDA approves first once-daily oral treatment for acromegaly
Paltusotine is now FDA-approved as medical therapy for patients with acromegaly. This is the first oral somatostatin receptor ligand with approval as a single daily dose and the first oral drug app...
Code & Tools
Pituitary tumors are abnormal growths that develop in the pituitary gland, a small gland located at the base of the brain. These tumors can cause h...
Pituitary Tumor: A tumor that arises from the pituitary gland, located at the base of the brain. Dataset Details: Number of Images: 7,023 i...
Pituitary tumors are a group of benign, rarely malignant neoplasms of the anterior lobe (adenohypophysis) or posterior lobe (neurohypophysis) of th...
- Pituitary tumor is a tumor that forms in the pituitary gland near the brain that can cause changes in hormoneslevel in the body - Most pituitary ...
This repository ( Adeno Predict) serves the purpose of applying machine learning algorithms to predict the consistency of pituitary macroadenomas f...
Recent Preprints
Pituitary diseases - Latest research and news
Research siloes slow the translation of scientific discovery to patient care and limit progress in improving treatments for Cushing disease to incremental advances. Facilitating collaborative effor...
Pituitary Gland - Recent articles and discoveries - Springer Link
- Overview Pituitarypublishes basic and clinical articles in all fields of neuroendocrinology on pathophysiology, diagnosis and treatment of pituitary... Publishing modelHybrid Jour...
An overview of hypopituitarism's causes
Damage to the hypothalamus, hypothalamic-pituitary pathway, pituitary gland, or neurohypophyseal gland for various reasons leads to pituitary dysfunction, a disorder characterized by insufficient s...
Pituitary Adenoma - StatPearls - NCBI Bookshelf
Management involves individualized therapy, including medical treatment, transsphenoidal surgery, or radiotherapy, depending on tumor type and functional status.
Physiology and Diseases of the Hypothalamic-Pituitary Axis in ...
# Physiology and Diseases of the Hypothalamic-Pituitary Axis in the Elderly Kevin C.J. Yuen, MD, FRCP (UK), FACE, FEAA,Eunisse W.R. Chua, BS, MS, MD Candidate,Alissya S.M. Yuen, BS,Mercedes Martine...
Latest Developments
Recent research in pituitary gland disorders highlights advances in understanding conditions such as Cushing syndrome, with recent reviews discussing its causes, diagnosis, and management (Nature). Notably, autoimmune hypophysitis, including cases associated with systemic lupus erythematosus, has been documented, emphasizing the autoimmune nature of some pituitary disorders (Frontiers). Additionally, new treatment approaches and clinical guidelines are being developed, including updates on therapeutic outcomes for acromegaly and management strategies for aggressive pituitary tumors and carcinomas (Nature Reviews Endocrinology, UCL Discovery, CNS). Ongoing research and clinical trials continue to shape the evolving landscape of pituitary disorder treatment (OHSU).
Sources
Frequently Asked Questions
What tests are recommended for diagnosing Cushing's syndrome?
Nieman et al. (2008) in "The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline" recommend initial testing with late-night salivary cortisol, 1 mg dexamethasone suppression test, or 24-hour urinary free cortisol after excluding exogenous glucocorticoids. Testing targets patients with multiple progressive features or adrenal incidentalomas. Positive results require follow-up confirmation.
How is hyperprolactinemia diagnosed and treated?
Melmed et al. (2011) in "Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline" present evidence-based approaches to identify causes including prolactinomas and drug-induced states. Treatment involves dopamine agonists for prolactinomas in nonpregnant and pregnant patients. Management addresses elevated prolactin levels systematically.
What is the standard treatment for acromegaly?
Katznelson et al. (2014) in "Acromegaly: An Endocrine Society Clinical Practice Guideline" recommend biochemical assessment with IGF-1 and GH levels, followed by transsphenoidal surgery as first-line therapy. Medical options include somatostatin analogs, GH receptor antagonists, or dopamine agonists as monotherapy or combination. Radiotherapy serves as adjunctive treatment.
What causes multiple endocrine neoplasia type 1 (MEN1)?
Chandrasekharappa et al. (1997) in "Positional Cloning of the Gene for Multiple Endocrine Neoplasia-Type 1" identified the MEN1 gene on chromosome 11q13 through DNA sequencing. MEN1 is an autosomal dominant syndrome with tumors in parathyroids, enteropancreatic tissues, and anterior pituitary. The gene discovery enables genetic testing.
What is the recommended therapy for hypothyroidism related to pituitary disorders?
Jonklaas et al. (2014) in "Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement" conclude that levothyroxine monotherapy is the standard for hypothyroidism. No strong evidence supports superiority of levothyroxine-liothyronine combinations or thyroid extracts. This applies to secondary hypothyroidism from pituitary failure.
How are pituitary adenomas managed?
Management of pituitary adenomas involves individualized therapy including medical treatment, transsphenoidal surgery, or radiotherapy based on tumor type and functional status, as described in "Pituitary Adenoma - StatPearls - NCBI Bookshelf". Pituitary tumors account for about 15% of brain tumors and are mostly benign. Early diagnosis supports effective intervention.
Open Research Questions
- ? How can research silos be overcome to accelerate translation of discoveries into targeted treatments for Cushing disease and pituitary neuroendocrine tumors?
- ? What are the prevalence and incidence rates of hypopituitarism in adults from international studies, and what factors contribute to hypothalamic-pituitary pathway damage?
- ? How does aging affect physiology and diseases of the hypothalamic-pituitary axis, particularly in the elderly?
- ? Can machine learning models using MRI parameters accurately predict the consistency of pituitary macroadenomas to guide surgical planning?
Recent Trends
FDA approvals in September 2025 introduced paltusotine (Palsonify) and Crinetics' once-daily oral treatments for acromegaly caused by pituitary adenomas, marking the first oral somatostatin receptor ligands as primary therapy.
Preprints emphasize research silos slowing Cushing disease progress and note hypopituitarism from hypothalamic-pituitary damage with international prevalence data.
Pituitary journal reports 357,436 downloads in 2024 and a 3.4 impact factor, alongside GitHub projects using U-Net for MRI-based pituitary tumor segmentation and classification across 7,023 images.
Research Pituitary Gland Disorders and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Pituitary Gland Disorders and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.